{"entity":{"id":"nct03319628","kind":"trial","name":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","aka":[],"tldr":"A phase 1/2 trial of upifitamab rilsodotin in ovarian cancer and non-small-cell lung cancer, run by Mersana Therapeutics, active and no longer recruiting.","summary":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b is a phase 1/2 interventional study registered as NCT03319628 by Mersana Therapeutics, with 523 participants enrolled, started 2017-12-12 and due to reach its primary completion in 2023-05-31. Interventions recorded: upifitamab rilsodotin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03319628","url":"https://clinicaltrials.gov/study/NCT03319628"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mersana"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03319628","phase":"1/2","setting":"A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b","sponsor":"Mersana Therapeutics","enrolled":523,"outcomes":[]},"route":"/trials/nct03319628/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/"}],"drug":[{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","route":"/drugs/upifitamab-rilsodotin/"}]}}